Skip to main content
S. 1250 118th Congress Senate

Drug-price Transparency for Consumers Act of 2023

Official title: A bill to amend title XI of the Social Security Act to require that direct-to-consumer advertisements for drugs and biologicals include an appropriate disclosure of pricing information.

Introduced: April 20, 2023 Introduced by: Richard J. Durbin Democratic · Illinois See on congress.gov
Health Administrative law and regulatory proceduresCivil actions and liabilityDepartment of Health and Human ServicesHealth care costs and insurance
More subjectsShow fewer subjects
Marketing and advertisingPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 20, 2023
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)
Apr 20, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action April 20, 2023

Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)

 Plain-English summary Congressional Research Service

Drug-price Transparency for Consumers Act of 2023 or the DTC Act of 2023

This bill requires consumer advertisements for drugs and biologicals to include certain price information if the drug or biological is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. The requirement does not apply to advertisements for drugs or biologicals with a wholesale cost of less than $35 for a one-month supply.

Each violation of this requirement is subject to a civil penalty of not more than $100,000.


 Related & companion bills 1
  • HR 5958 Identical bill Drug-price Transparency for Consumers Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 5
All 5 Democratic 3 Republican 1 Independent 1
D
Smith, Tina
Minnesota · Sep 7, 2023
 D
Baldwin, Tammy
Wisconsin · Apr 20, 2023
 D
Blumenthal, Richard
Connecticut · Apr 20, 2023
 R
Grassley, Chuck
Iowa · Apr 20, 2023
 I
King, Angus S., Jr.
Maine · Apr 20, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1250: Drug-price Transparency for Consumers Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1250/
MLA
"S. 1250: Drug-price Transparency for Consumers Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1250/.
Bluebook (legal)
S. 1250, 118th Cong. (2026), https://openamerica.io/bill/118-S-1250/.
Markdown link
[S. 1250: Drug-price Transparency for Consumers Act of 2023](https://openamerica.io/bill/118-S-1250/)
Report a problem